Loading...
01/11 04:03
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals strong financial performance with a 6% revenue growth and a 14% EPS increase. The company maintains solid guidance and operational efficiency despite currency and tariff challenges. Share repurchases and a raised EPS guidance further indicate confidence. Although there are concerns in fertility and vision care markets, growth in myopia management and private label strategies remain robust. The Q&A section highlights management's optimism, especially with MiSight's growth, supporting a positive sentiment. Given the lack of market cap data, a moderate positive reaction (2% to 8%) is anticipated.
Consolidated Revenues $1,002,000,000, up 6% year over year (up 7% organically).
CooperVision Revenues $670,000,000, up 5% year over year (up 7% organically).
CooperSurgical Revenues $333,000,000, up 8% year over year (up 7% organically).
Non GAAP Earnings Per Share (EPS) $0.96, up 14% year over year.
Consolidated Gross Margin 68%, up from 67.3% year over year, driven by efficiency gains and mix.
Operating Expenses Increased 6%, but declined as a percent of revenue to 43.1%, driven by leverage in several functional areas.
Research and Development (R&D) Expenses Increased 21%, reflecting higher investments for product development.
Consolidated Operating Income Up 11%, improving the operating margin to 24.9%.
Interest Expense $23,500,000.
Effective Tax Rate 14.6%.
Free Cash Flow $18,000,000.
Capital Expenditures (CapEx) $78,000,000.
Net Debt Increased slightly to $2,470,000,000.
Bank Defined Leverage Ratio Reduced to 1.9 times.
Share Repurchases Approximately 537,000 shares for roughly $40,600,000.
Revenue Guidance for Fiscal Year 2025 $4,110,000,000 to $4,150,000,000, up roughly 5.5% to 6.5%.
CooperVision Revenue Guidance $2,760,000,000 to $2,790,000,000, up roughly 6% to 7%.
CooperSurgical Revenue Guidance $1,350,000,000 to $1,360,000,000, up 5% to 6%.
Non GAAP EPS Guidance $4.05 to $4.11, growth of roughly 10% to 11.5% year over year.
Free Cash Flow Guidance Expected to be in the range of $350,000,000 to $400,000,000.
Tariff Impact Expected negative impact of roughly $4,000,000 to cost of goods.
Currency Impact Roughly 0.5% headwind to revenues and 1% headwind to earnings.
New Product Launches: Launched MyDay Energous with digital boost technology in Canada, receiving positive feedback and significant requests for fitting sets.
Product Expansion: Expanded MyDay toric parameter range in North America and Europe, with plans for Asia Pacific.
Product Upgrades: Upgraded Clarity One Day Sphere with WetLock technology in Japan.
Myopia Management Growth: MiSight revenue reached $25 million, up 35%, with a focus on reducing upfront fitting barriers through promotions.
Market Expansion: Increased availability of daily silicone hydrogel lenses in new markets and channels.
Market Growth Expectations: Adjusted organic growth expectations for CooperVision to 6%-7% and for CooperSurgical to 3.5%-4.5%.
Fertility Market Trends: Fertility revenues were softer than expected, particularly in Asia Pacific, with a decline in fertility cycles.
Operational Efficiency: Achieved operational improvements and OpEx leverage, driving double-digit non-GAAP earnings growth.
R&D Investment: Increased R&D expenses by 21% to support new product development.
Gross Margin Improvement: Consolidated gross margin improved to 68% from 67.3%.
Strategic Shift in Pricing: Expecting to pass along inflationary price increases, with potential for future price increases in response to tariffs.
Focus on Market Share: Maintaining a strategy to take market share despite lower market growth expectations.
Market Growth Expectations: The company has lowered its market growth expectations for contact lenses to 4-6% from 5-7%, reflecting a return to historical growth rates and general market softness.
Fertility Market Challenges: Fertility revenues were softer than expected, particularly in Asia Pacific, due to declining fertility cycles and tighter cash management by clinics, leading to delays in capital purchases.
Tariff Impact: The company anticipates a negative impact of approximately $4 million from tariffs on cost of goods this year, with a potential 3% headwind to earnings in fiscal 2026 if tariffs remain unchanged.
Channel Inventory Pressure: There is ongoing pressure from channel inventory as distributors and retailers are tightening their purchasing habits, leading to consumers buying shorter supplies of contact lenses.
Economic Factors: Economic difficulties are causing consumers to delay capital purchases in fertility clinics, impacting overall market growth.
Currency Headwinds: The company expects a 0.5% headwind to revenues and a 1% headwind to earnings due to currency fluctuations.
Operational Efficiency: Despite challenges, the company is achieving operational efficiencies that are helping to offset some of the negative impacts from tariffs and currency fluctuations.
Consolidated Organic Revenue Growth: 7% growth driven by double-digit growth in daily silicone hydrogel lenses and surgical portfolio.
Product Launches: Launched MyDay Energous in Canada and upgraded Clarity One Day Sphere in Japan.
Myopia Management Portfolio: MiSight revenue reached $25 million, up 35%, with a focus on reducing upfront fitting barriers.
Private Label Growth: Private label business is growing faster than branded business.
Operational Improvements: Continued operational improvements and OpEx leverage driving double-digit non-GAAP earnings growth.
Revenue Guidance: Tightened to $4.11 billion to $4.15 billion, reflecting a 5.5% to 6.5% increase.
CooperVision Revenue Guidance: Adjusted to $2.76 billion to $2.79 billion, up 6% to 7%.
CooperSurgical Revenue Guidance: Adjusted to $1.35 billion to $1.36 billion, up 3.5% to 4.5%.
EPS Guidance: Raised to $4.05 to $4.11, reflecting a 10% to 11.5% year-over-year growth.
CapEx: Expected to be $78 million with free cash flow projected at $350 million to $400 million.
Tariff Impact: Expected negative impact of $4 million on cost of goods.
Currency Impact: Expected 0.5% headwind to revenues and 1% headwind to earnings.
Share Repurchase: Approximately 537,000 shares were repurchased for roughly $40,600,000 during the quarter. There remains $215,800,000 available under the Board approved $1,000,000,000 repurchase plan.
The earnings call indicates positive sentiment with strong product development, optimistic revenue guidance, and expected market share gains. The strategic plans for MyDAY and MiSight, along with anticipated operating margin expansion and free cash flow improvements, contribute to this outlook. Despite some gross margin pressure, the overall sentiment from the call, including analyst reactions, suggests a positive impact on stock price.
The earnings call presents a mixed outlook. Basic financial performance and product development are positive, but the Q&A reveals concerns over market share loss in Asia, unclear management responses, and margin pressures. The raised EPS guidance and strong MySight growth are positives, but aggressive pricing and Clariti challenges pose risks. Overall, the sentiment is neutral, with a balanced mix of positive and negative factors.
The earnings call reveals strong financial performance with a 6% revenue growth and a 14% EPS increase. The company maintains solid guidance and operational efficiency despite currency and tariff challenges. Share repurchases and a raised EPS guidance further indicate confidence. Although there are concerns in fertility and vision care markets, growth in myopia management and private label strategies remain robust. The Q&A section highlights management's optimism, especially with MiSight's growth, supporting a positive sentiment. Given the lack of market cap data, a moderate positive reaction (2% to 8%) is anticipated.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
